- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03298113
Comparative Study to Assess an Advanced Skin Protectant in the Management of Incontinence-associated Dermatitis
Effects of an Advanced Skin Protectant in the Management of Incontinence-associated Dermatitis Compared to Hospital Standard Care Practice: an Exploratory Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
East Flanders
-
Gent, East Flanders, Belgium, 9000
- Universitair Ziekenhuis Gent
-
-
-
-
-
Berlin, Germany, 10117
- Charité - Universitätsmedizin Berlin
-
-
-
-
-
Southampton, United Kingdom, SO16 6YD
- University Hospital Southampton
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Is the patient 18 years or older?
- Has the patient or their legally authorized representative signed the Informed Consent Form?
- Does the patient have IAD category 1A (IAD 1A: persistent redness without clinical signs of infection) or IAD category 2A (IAD 2A: skin loss without clinical signs of infection) in the study area (study area: the sacral region going down to the upper thighs, bordered approximately 5 cm below the gluteal fold?
- Is the patient incontinent and does stool and/or urine come into direct contact with the skin?
- Is the patient able to be turned/positioned with regard to skin assessment and photo documentation?
- Is there a reasonable expectation that the patient will remain in the hospital setting for at least 7 days?
Exclusion Criteria:
- Is the patient pregnant or breast feeding?
- Does the patient have a known hypersensitivity or allergy to acrylate or cyanoacrylate?
- Does the patient have a stage II, III, IV or unstageable pressure ulcer or other suspected deep tissue injury in the study area?
- Does the patient require topical treatment due to a fungal, bacterial or viral infection in the study area?
- Does the patient require treatment with topical medication or product other than IAD treatment in the study area?
- Does the patient have any other local dermatological disease or skin condition interfering with this study?
- Does the patient have any medical condition (e.g. end of life, planned elective surgery) that in the opinion of the investigator should exclude him/her from participating in the study?
- Does the patient participate in another study with a known or implied effect on skin barrier function?
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cavilon Advanced Skin Protectant
Product applicator contains liquid barrier and is applied according to the 3M manufacturer's instructions for use.
|
Applicator contains a polymeric-cyanoacrylate solution intended to cover and protect intact or damaged skin.
Upon application to skin, the liquid dries rapidly to form a primary long-lasting waterproof, highly durable film barrier.
|
Other: IAD Hospital Standard Care
Marketed products are applied according to the IAD hospital standard care routine.
|
Devices such as local skin protectants will be used according to the hospital IAD care regime and under consideration of the respective manufacturers' instructions for use.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Healing of IAD
Time Frame: up to 21 days depending on length of hospitalization
|
Number and percentage of patients completely healed (skin free of any IAD signs, including erythema, based on a structured skin assessment according to the GLOBIAD criteria (GLOBIAD: Ghent Global IAD Categorization Tool) Note: Due to the exploratory design no formal a priori hypothesis was defined for this study. The outcome measure type for all endpoints is "other pre-specified". The effects were analyzed using descriptive statistics. No confirmatory statements can be made about the effects and no comparative statements are possible. The sponsor decided to early terminate the study after 20 evaluable patients for the intention-to-treat analysis. Reason for the early termination was the slow enrollment rate of patients and overall short length of stay in hospital. |
up to 21 days depending on length of hospitalization
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement of IAD Category
Time Frame: Up to 21 days depending on length of hospitalization
|
Number and percentage of patients improved with regard to IAD category
|
Up to 21 days depending on length of hospitalization
|
Re-epithelialization of Skin Loss
Time Frame: up to 21 days depending on length of hospitalization
|
Number and percentage of patients with 100% re-epithelialization of skin loss based on structured skin assessment (skin loss: skin is moist, as the epidermal layer is missing).
|
up to 21 days depending on length of hospitalization
|
Time to Heal IAD
Time Frame: Up to 21 days depending on length of hospitalization
|
Time to complete healing of IAD in the terms of days of treatment (skin free of any IAD signs, including erythema, based on a structured skin assessment according to the GLOBIAD criteria (GLOBIAD: Ghent Global IAD Categorization Tool)
|
Up to 21 days depending on length of hospitalization
|
Time to Improve in IAD Category
Time Frame: Up to 21 days depending on length of hospitalization
|
Time to improve in IAD category in the terms of days of treatment.
|
Up to 21 days depending on length of hospitalization
|
Prevention of Skin Loss
Time Frame: up to 21 days depending on length of hospitalization
|
Protection of IAD category 1 patients from developing IAD category 2
|
up to 21 days depending on length of hospitalization
|
Prevention of IAD Recurrence
Time Frame: up to 21 days depending on length of hospitalization
|
Protection of completely healed patients from recurrence of IAD during the study.
|
up to 21 days depending on length of hospitalization
|
Product Cost: IAD 1A
Time Frame: up to 21 days depending on length of hospitalization
|
Mean average daily product cost per patient for IAD 1A treatment based on skin protectant utilization such as type of skin protectant, frequency of application and days of treatment. Note: One patient in the group treated with Cavilon Advanced Skin Protectant stayed only one day in the study due to an unrelated Severe Adverse Event at night. This had an impact on the product cost calculation. The application interval for Cavilon Advanced Skin Protectant in this study was three days (D1, D4, D7, D10, D13, D16, D19) , while the use of IAD products for standard hospital care was based on manufacturer recommendations, which could correspond to a daily interval with multiple applications. |
up to 21 days depending on length of hospitalization
|
Product Cost : IAD 2A
Time Frame: up to 21 days depending on length of hospitalization
|
Mean average daily cost per patient for IAD 2A treatment based on skin protectant utilization such as type of skin protectant, frequency of application and days of treatment
|
up to 21 days depending on length of hospitalization
|
Use of Resources Involved in IAD Therapy
Time Frame: Up to 21 days depending on length of hospitalization
|
Additional appointments with specialists involved in IAD therapy
|
Up to 21 days depending on length of hospitalization
|
Nursing Time Related to Cleansing
Time Frame: up to 21 days depending on length of hospitalization
|
Nursing time to clean up incontinence episode
|
up to 21 days depending on length of hospitalization
|
Nursing Time Related to Product Application
Time Frame: up to 21 days depending on length of hospitalization
|
Nursing time to administer skin protectants for IAD treatment
|
up to 21 days depending on length of hospitalization
|
Pain Related to Cleansing: IAD 1A
Time Frame: up to 21 days depending on length of hospitalization
|
Pain scores related to clean up incontinence episode for IAD 1A patients. The table details the reduction in pain experienced by subjects able to report their last recorded cleaning event relative to baseline. More extreme negative values denote a larger reduction in pain. For cleansing, IAD 1A patients treated with Cavilon Advanced Skin Protectant saw no change in pain due to having no pain reported at baseline nor last visit. Note: For this study the Wong-Baker FACES® Pain Rating Scale was used for patients able to report pain. Faces with different expressions from smiling to crying facilitated the communication as anchor for pain intensity scale (scores: 0, 2, 4, 6, 8, 10), with higher score indicating more pain. |
up to 21 days depending on length of hospitalization
|
Pain Related to Cleansing: IAD 2A
Time Frame: up to 21 days depending on length of hospitalization
|
Pain scores related to clean up incontinence episode for IAD 2A patients. The table details the reduction in pain experienced by subjects able to report their last recorded cleaning event relative to baseline. More extreme negative values denote a larger reduction in pain. Note: For this study the Wong-Baker FACES® Pain Rating Scale was used for patient able to report pain. Faces with different expressions from smiling to crying facilitated the communication as anchor for pain intensity scale (scores: 0, 2 , 4, 6, 8, 10), with higher score indicating more pain. |
up to 21 days depending on length of hospitalization
|
Pain Related to Product Application: IAD 1A
Time Frame: up to 21 days depending on length of hospitalization
|
Pain scores related to application of skin protectants for IAD 1A patients (Wong-Baker FACES® Pain Rating Scale). The table details the reduction in pain experienced by subjects able to report at their last recorded application event relative to baseline. Note: For this study the Wong-Baker FACES® Pain Rating Scale was used for patient able to report pain. Faces with different expressions from smiling to crying facilitated the communication as anchor for pain intensity scale (scores: 0, 2 , 4, 6, 8, 10), with higher score indicating more pain. |
up to 21 days depending on length of hospitalization
|
Pain Related to Product Application: IAD 2A
Time Frame: up to 21 days depending on length of hospitalization
|
Pain scores related to application of skin protectants for IAD 2A patients (Wong-Baker FACES® Pain Rating Scale). The table details the reduction in pain experienced by subjects able to report at their last recorded application event relative to baseline. More extreme negative values denote a larger reduction in pain. Note: For this study the Wong-Baker FACES® Pain Rating Scale was used for patient able to report pain. Faces with different expressions from smiling to crying facilitated the communication as anchor for pain intensity scale (scores: 0, 2 , 4, 6, 8, 10), with higher score indicating more pain. |
up to 21 days depending on length of hospitalization
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Matthew M. Cooper, MD, 3M
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLIN-PROT-EU-05-293312
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Incontinence-associated Dermatitis
-
ScotiadermNot yet recruitingIncontinence-associated Dermatitis | Moisture Associated Skin Damage (MASD) (E.G., Incontinence-Associated Dermatitis [IAD], Perspiration, Drainage) | Fecal Incontinence Incontinence-associated Dermatitis
-
ScotiadermNot yet recruitingIntertrigo | Incontinence-associated Dermatitis | Moisture Associated Skin Damage (MASD) (E.G., Incontinence-Associated Dermatitis [IAD], Perspiration, Drainage)
-
3MTerminatedIncontinence Associated DermatitisUnited States
-
Tan Tock Seng HospitalTerminatedIncontinence-associated DermatitisSingapore
-
University of the PhilippinesCalmoseptine, Inc.CompletedIncontinence Associated DermatitisPhilippines
-
Essity Hygiene and Health ABNot yet recruitingIncontinence-associated DermatitisSweden
-
ScotiadermNot yet recruitingIntertrigo | Incontinence-associated Dermatitis | Moisture Associated Skin Damage
-
Charite University, Berlin, GermanyRecruiting
-
University Ghent3MCompletedDiaper Rash | Incontinence-associated Dermatitis | Irritant Contact DermatitisBelgium
-
University Ghent3MTerminatedPressure Ulcer | Diaper Rash | Incontinence-associated Dermatitis | Irritant Contact Dermatitis Due to IncontinenceBelgium
Clinical Trials on Cavilon Advanced Skin Protectant
-
3MTerminated
-
Medline IndustriesCompleted
-
Jessa HospitalWithdrawnSkin Diseases | Head and Neck Cancer | Radiation Toxicity | Radiodermatitis | Radiation DermatitisBelgium
-
Mayo ClinicCompletedRadiation DermatitisUnited States
-
University Ghent3MRecruitingWound of Skin | Irritant Dermatitis | Stoma Site DermatitisBelgium
-
3MTerminatedIncontinence Associated DermatitisUnited States
-
Tan Tock Seng HospitalTerminatedIncontinence-associated DermatitisSingapore
-
Charite University, Berlin, GermanyRecruiting
-
Medline IndustriesEnrolling by invitationErythema | Skin Folds | Lesion Skin | MacerationUnited States